Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Hydrazines
  • Leukemia, Myeloid, Acute
  • Sulfonamides

abstract

  • Cloretazine has significant activity and modest extramedullary toxicity in elderly patients with AML or high-risk MDS. Response rates remain consistent despite increasing age and comorbidity.

publication date

  • January 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.0961

PubMed ID

  • 17146105

Additional Document Info

start page

  • 25

end page

  • 31

volume

  • 25

number

  • 1